KISPLYX, known generically as lenvatinib, is a prescription medication used in the treatment of certain types of cancer. It is specifically indicated for the treatment of advanced renal cell carcinoma (kidney cancer), in combination with other drugs, and for differentiated thyroid cancer and hepatocellular carcinoma (liver cancer) in patients who require systemic therapy. KISPLYX works by inhibiting multiple protein kinases, which are involved in the growth and spread of cancer cells, as well as the formation of new blood vessels that tumors need to grow (angiogenesis). By targeting these pathways, KISPLYX helps to slow down the progression of cancer and may reduce the size of tumors. It is available in capsule form and is taken orally. As with any cancer therapy, it may cause a range of side effects, and its use should be closely monitored by a healthcare professional.